Works matching IS 00071188 AND DT 2014 AND VI 171 AND IP 19

Results: 18

Vasorelaxant effects of novel Kv 7.4 channel enhancers ML213 and NS15370.

Published in:

2014

By:

Jepps, T A;
Bentzen, B H;
Stott, J B;
Povstyan, O V;
Sivaloganathan, K;
Dalby-Brown, W;
Greenwood, I A

Publication type:

journal article

PAR1-dependent COX-2/PGE2 production contributes to cell proliferation via EP2 receptors in primary human cardiomyocytes.

Published in:

2014

By:

Chien, Peter Tzu-Yu;
Hsieh, Hsi-Lung;
Chi, Pei-Ling;
Yang, Chuen-Mao

Publication type:

journal article

CFTR potentiators partially restore channel function to A561E-CFTR, a cystic fibrosis mutant with a similar mechanism of dysfunction as F508del-CFTR.

Published in:

2014

By:

Wang, Yiting;
Liu, Jia;
Loizidou, Avgi;
Bugeja, Luc A;
Warner, Ross;
Hawley, Bethan R;
Cai, Zhiwei;
Toye, Ashley M;
Sheppard, David N;
Li, Hongyu

Publication type:

journal article

Mexiletine as a treatment for primary erythromelalgia: normalization of biophysical properties of mutant L858F NaV 1.7 sodium channels.

Published in:

2014

By:

Cregg, R;
Cox, J J;
Bennett, D L H;
Wood, J N;
Werdehausen, R

Publication type:

journal article

Overexpression of oxytocin receptors in the hypothalamic PVN increases baroreceptor reflex sensitivity and buffers BP variability in conscious rats.

Published in:

British Journal of Pharmacology, 2014, v. 171, n. 19, p. 4385, doi. 10.1111/bph.12776

By:

Lozić, Maja;
Greenwood, Michael;
Šarenac, Olivera;
Martin, Andrew;
Hindmarch, Charles;
Tasić, Tatjana;
Paton, Julian;
Murphy, David;
Japundžić ‐ Žigon, Nina

Publication type:

Article

CFTR potentiators partially restore channel function to A561 E-CFTR, a cystic fibrosis mutant with a similar mechanism of dysfunction as F508del- CFTR.

Published in:

British Journal of Pharmacology, 2014, v. 171, n. 19, p. 4490, doi. 10.1111/bph.12791

By:

Wang, Yiting;
Liu, Jia;
Loizidou, Avgi;
Bugeja, Luc A;
Warner, Ross;
Hawley, Bethan R;
Cai, Zhiwei;
Toye, Ashley M;
Sheppard, David N;
Li, Hongyu

Publication type:

Article

Pharmacological regulators of autophagy and their link with modulators of lupus disease.

Published in:

British Journal of Pharmacology, 2014, v. 171, n. 19, p. 4337, doi. 10.1111/bph.12792

By:

Gros, Frédéric;
Muller, Sylviane

Publication type:

Article

Quercetin attenuates doxorubicin cardiotoxicity by modulating Bmi-1 expression.

Published in:

British Journal of Pharmacology, 2014, v. 171, n. 19, p. 4440, doi. 10.1111/bph.12795

By:

Dong, Qinghua;
Chen, Long;
Lu, Qunwei;
Sharma, Sherven;
Li, Lei;
Morimoto, Sachio;
Wang, Guanyu

Publication type:

Article

PAR1-dependent COX-2/ PGE2 production contributes to cell proliferation via EP2 receptors in primary human cardiomyocytes.

Published in:

British Journal of Pharmacology, 2014, v. 171, n. 19, p. 4504, doi. 10.1111/bph.12794

By:

Chien, Peter Tzu ‐ Yu;
Hsieh, Hsi ‐ Lung;
Chi, Pei ‐ Ling;
Yang, Chuen ‐ Mao

Publication type:

Article

Issue Information.

Published in:: British Journal of Pharmacology, 2014, v. 171, n. 19, p. i, doi. 10.1111/bph.12388
Publication type:: Article

Ulinastatin activates haem oxygenase 1 antioxidant pathway and attenuates allergic inflammation.

Published in:

British Journal of Pharmacology, 2014, v. 171, n. 19, p. 4399, doi. 10.1111/bph.12780

By:

Song, Dongmei;
Song, Geng;
Niu, Yinghao;
Song, Wei;
Wang, Jiantao;
Yu, Lei;
Yang, Jianwang;
Lv, Xin;
Steinberg, Harry;
Liu, Shu Fang;
Wang, Baoshan

Publication type:

Article

Pharmacological bronchodilation is partially mediated by reduced airway wall stiffness.

Published in:

British Journal of Pharmacology, 2014, v. 171, n. 19, p. 4376, doi. 10.1111/bph.12781

By:

Ansell, T K;
Noble, P B;
Mitchell, H W;
McFawn, P K

Publication type:

Article

Identification of an old antibiotic clofoctol as a novel activator of unfolded protein response pathways and an inhibitor of prostate cancer.

Published in:

British Journal of Pharmacology, 2014, v. 171, n. 19, p. 4478, doi. 10.1111/bph.12800

By:

Wang, Minghua;
Shim, Joong Sup;
Li, Ruo ‐ Jing;
Dang, Yongjun;
He, Qingli;
Das, Manisha;
Liu, Jun O

Publication type:

Article

Mexiletine as a treatment for primary erythromelalgia: normalization of biophysical properties of mutant L858 F NaV1.7 sodium channels.

Published in:

British Journal of Pharmacology, 2014, v. 171, n. 19, p. 4455, doi. 10.1111/bph.12788

By:

Cregg, R;
Cox, J J;
Bennett, D L H;
Wood, J N;
Werdehausen, R

Publication type:

Article

Targeting multiple cannabinoid anti-tumour pathways with a resorcinol derivative leads to inhibition of advanced stages of breast cancer.

Published in:

British Journal of Pharmacology, 2014, v. 171, n. 19, p. 4464, doi. 10.1111/bph.12803

By:

Murase, Ryuichi;
Kawamura, Rumi;
Singer, Eric;
Pakdel, Arash;
Sarma, Pranamee;
Judkins, Jonathon;
Elwakeel, Eiman;
Dayal, Sonali;
Martinez ‐ Martinez, Esther;
Amere, Mukkanti;
Gujjar, Ramesh;
Mahadevan, Anu;
Desprez, Pierre ‐ Yves;
McAllister, Sean D

Publication type:

Article

Purinergic neuromuscular transmission in the gastrointestinal tract; functional basis for future clinical and pharmacological studies.

Published in:

British Journal of Pharmacology, 2014, v. 171, n. 19, p. 4360, doi. 10.1111/bph.12802

By:

Jiménez, Marcel;
Clavé, Pere;
Accarino, Anna;
Gallego, Diana

Publication type:

Article

Vasorelaxant effects of novel Kv7.4 channel enhancers ML213 and NS15370.

Published in:

British Journal of Pharmacology, 2014, v. 171, n. 19, p. 4413, doi. 10.1111/bph.12805

By:

Jepps, T A;
Bentzen, B H;
Stott, J B;
Povstyan, O V;
Sivaloganathan, K;
Dalby ‐ Brown, W;
Greenwood, I A

Publication type:

Article

Molecular basis of agonist docking in a human GPR103 homology model by site-directed mutagenesis and structure-activity relationship studies.

Published in:

British Journal of Pharmacology, 2014, v. 171, n. 19, p. 4425, doi. 10.1111/bph.12808

By:

Neveu, C;
Dulin, F;
Lefranc, B;
Galas, L;
Calbrix, C;
Bureau, R;
Rault, S;
Chuquet, J;
Boutin, J A;
Guilhaudis, L;
Ségalas ‐ Milazzo, I;
Vaudry, D;
Vaudry, H;
Santos, J Sopkova ‐ de Oliveira;
Leprince, J

Publication type:

Article

Works matching IS 00071188 AND DT 2014 AND VI 171 AND IP 19

Vasorelaxant effects of novel Kv 7.4 channel enhancers ML213 and NS15370.

PAR1-dependent COX-2/PGE2 production contributes to cell proliferation via EP2 receptors in primary human cardiomyocytes.

CFTR potentiators partially restore channel function to A561E-CFTR, a cystic fibrosis mutant with a similar mechanism of dysfunction as F508del-CFTR.

Mexiletine as a treatment for primary erythromelalgia: normalization of biophysical properties of mutant L858F NaV 1.7 sodium channels.

Overexpression of oxytocin receptors in the hypothalamic PVN increases baroreceptor reflex sensitivity and buffers BP variability in conscious rats.

CFTR potentiators partially restore channel function to A561 E-CFTR, a cystic fibrosis mutant with a similar mechanism of dysfunction as F508del- CFTR.

Pharmacological regulators of autophagy and their link with modulators of lupus disease.

Quercetin attenuates doxorubicin cardiotoxicity by modulating Bmi-1 expression.

PAR1-dependent COX-2/ PGE<sub>2</sub> production contributes to cell proliferation via EP<sub>2</sub> receptors in primary human cardiomyocytes.

Issue Information.

Ulinastatin activates haem oxygenase 1 antioxidant pathway and attenuates allergic inflammation.

Pharmacological bronchodilation is partially mediated by reduced airway wall stiffness.

Identification of an old antibiotic clofoctol as a novel activator of unfolded protein response pathways and an inhibitor of prostate cancer.

Mexiletine as a treatment for primary erythromelalgia: normalization of biophysical properties of mutant L858 F Na<sub>V</sub>1.7 sodium channels.

Targeting multiple cannabinoid anti-tumour pathways with a resorcinol derivative leads to inhibition of advanced stages of breast cancer.

Purinergic neuromuscular transmission in the gastrointestinal tract; functional basis for future clinical and pharmacological studies.

Vasorelaxant effects of novel K<sub>v</sub>7.4 channel enhancers ML213 and NS15370.

Molecular basis of agonist docking in a human GPR103 homology model by site-directed mutagenesis and structure-activity relationship studies.